Systematically Understanding the Immunity Leading to CRPC Progression

Overview

Journal PLoS Comput Biol

Specialty Biology

Date 2019 Sep 11

PMID 31504033

Citations 18

Authors

Zhiwei Ji

Weiling Zhao

Hui-Kuan Lin

Xiaobo Zhou

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in American men. Androgen deprivation therapy (ADT) has become a standard treatment strategy for advanced PCa. Although a majority of patients initially respond to ADT well, most of them will eventually develop castration-resistant PCa (CRPC). Previous studies suggest that ADT-induced changes in the immune microenvironment (mE) in PCa might be responsible for the failures of various therapies. However, the role of the immune system in CRPC development remains unclear. To systematically understand the immunity leading to CRPC progression and predict the optimal treatment strategy in silico, we developed a 3D Hybrid Multi-scale Model (HMSM), consisting of an ODE system and an agent-based model (ABM), to manipulate the tumor growth in a defined immune system. Based on our analysis, we revealed that the key factors (e.g. WNT5A, TRAIL, CSF1, etc.) mediated the activation of PC-Treg and PC-TAM interaction pathways, which induced the immunosuppression during CRPC progression. Our HMSM model also provided an optimal therapeutic strategy for improving the outcomes of PCa treatment.

Citing Articles

Potential marker genes for chronic obstructive pulmonary disease revealed based on single-cell sequencing and Mendelian randomization analysis.

Sun G, Zhou Y, Han X, Che X, Yu S, Song D Aging (Albany NY). 2024; 16(10):8922-8943.

PMID: 38787375 PMC: 11164476. DOI: 10.18632/aging.205849.

DapBCH: a disease association prediction model Based on Cross-species and Heterogeneous graph embedding.

Shi W, Feng H, Li J, Liu T, Liu Z Front Genet. 2023; 14:1222346.

PMID: 37811150 PMC: 10556742. DOI: 10.3389/fgene.2023.1222346.

scFseCluster: a feature selection-enhanced clustering for single-cell RNA-seq data.

Wang Z, Xie X, Liu S, Ji Z Life Sci Alliance. 2023; 6(12).

PMID: 37788907 PMC: 10547911. DOI: 10.26508/lsa.202302103.

Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.

Hawlina S, Zorec R, Chowdhury H Life (Basel). 2023; 13(7).

PMID: 37511873 PMC: 10382052. DOI: 10.3390/life13071498.

Automated CT Pancreas Segmentation for Acute Pancreatitis Patients by combining a Novel Object Detection Approach and U-Net.

Deng Y, Lan L, You L, Chen K, Peng L, Zhao W Biomed Signal Process Control. 2023; 81.

PMID: 37304128 PMC: 10249746. DOI: 10.1016/j.bspc.2022.104430.

References

Wodarz D, Thomsen A . Effect of the CTL proliferation program on virus dynamics. Int Immunol. 2005; 17(9):1269-76. DOI: 10.1093/intimm/dxh303. View

Festuccia C, Gravina G, Biordi L, DAscenzo S, Dolo V, Ficorella C . Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate. 2009; 69(14):1529-37. DOI: 10.1002/pros.20995. View

Taplin M, Rajeshkumar B, Halabi S, Werner C, Woda B, Picus J . Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003; 21(14):2673-8. DOI: 10.1200/JCO.2003.11.102. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Fang L, Izumi K, Lai K, Liang L, Li L, Miyamoto H . Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013; 73(18):5633-46. PMC: 3833080. DOI: 10.1158/0008-5472.CAN-12-3228. View

Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K . The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004; 64(2):765-71. DOI: 10.1158/0008-5472.can-03-0130. View

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P . Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res. 2016; 76(8):2153-65. DOI: 10.1158/0008-5472.CAN-15-1965. View

Mukherjee R, McGuinness D, McCall P, Underwood M, Seywright M, Orange C . Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer. 2011; 104(12):1920-8. PMC: 3111196. DOI: 10.1038/bjc.2011.163. View

Shen C, Yang W, Chen H . The fate of regulatory T cells: survival or apoptosis. Cell Mol Immunol. 2013; 11(1):11-3. PMC: 4002139. DOI: 10.1038/cmi.2013.49. View

10.

Sica A, Schioppa T, Mantovani A, Allavena P . Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006; 42(6):717-27. DOI: 10.1016/j.ejca.2006.01.003. View

11.

Anderson A, Chaplain M . Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol. 1998; 60(5):857-99. DOI: 10.1006/bulm.1998.0042. View

12.

Chanmee T, Ontong P, Konno K, Itano N . Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014; 6(3):1670-90. PMC: 4190561. DOI: 10.3390/cancers6031670. View

13.

Mizokami A, Namiki M . Reconsideration of progression to CRPC during androgen deprivation therapy. J Steroid Biochem Mol Biol. 2014; 145:164-71. DOI: 10.1016/j.jsbmb.2014.03.015. View

14.

Lunemann J, Waiczies S, Ehrlich S, Wendling U, Seeger B, Kamradt T . Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol. 2002; 168(10):4881-8. DOI: 10.4049/jimmunol.168.10.4881. View

15.

Qiao W, Wang W, Laurenti E, Turinsky A, Wodak S, Bader G . Intercellular network structure and regulatory motifs in the human hematopoietic system. Mol Syst Biol. 2014; 10:741. PMC: 4299490. DOI: 10.15252/msb.20145141. View

16.

Zorn E, Nelson E, Mohseni M, Porcheray F, Kim H, Litsa D . IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5):1571-9. PMC: 1895505. DOI: 10.1182/blood-2006-02-004747. View

17.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

18.

Maia M, Hansen A . A comprehensive review of immunotherapies in prostate cancer. Crit Rev Oncol Hematol. 2017; 113:292-303. DOI: 10.1016/j.critrevonc.2017.02.026. View

19.

Su J, Zhang L, Zhang W, Choi D, Wen J, Jiang B . Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling. PLoS One. 2014; 9(1):e85059. PMC: 3903473. DOI: 10.1371/journal.pone.0085059. View

20.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View